Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia.
about
Imatinib in chronic myeloid leukemia: an overviewCurrent developments in molecular monitoring in chronic myeloid leukemiaA novel quantitative kinase assay using bacterial surface display and flow cytometryNilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis.Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.Harnessing preclinical mouse models to inform human clinical cancer trials.Monitoring response and resistance to treatment in chronic myeloid leukemia.Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia.ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan.Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disordersFirst-line treatment of chronic myeloid leukaemia.Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels.Management of Bcr-Abl-positive leukemias with dasatinib.How I treat newly diagnosed chronic phase CMLEarly responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalitiesMolecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications.Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib.Molecular diagnosis of myeloproliferative neoplasms.State-of-the-art in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors: evolutionary trends in diagnosis, monitoring and treatment.Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.Suboptimal responses in chronic myeloid leukemia: milestones and mechanisms.BCR-ABL1 kinase domain mutations: methodology and clinical evaluation.Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop.BCR-ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring.Chronic myeloid leukemia: In pursuit of perfection.New Methodologies in the Molecular Monitoring of CML.Monitoring disease burden in chronic myeloid leukemia: Past, present, and future.Molecular monitoring of chronic myeloid leukemia: present and future.Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations.Intelligent Techniques Using Molecular Data Analysis in Leukaemia: An Opportunity for Personalized Medicine Support System.Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop.Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis.Frequency of BCR-ABL Transcript Types in Syrian CML Patients.An In-House Method for Molecular Monitoring of BCR-ABL.Current survival measures reliably reflect modern sequential treatment in CML: correlation with prognostic stratifications.Use of imatinib mesylate in elderly patients in Northern Ireland: evidence of comparable haematological and molecular responses to younger patients.Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd.
P2860
Q26865086-967C96FA-EEC5-4856-9E0D-DC1D136E1F7EQ28066148-7A40547D-15A8-41CE-A329-3135E8856A8BQ28535179-7FB3244E-4E09-4E9C-9BA9-74C1628B82E4Q33439536-77B7874E-8EF1-40C6-8194-2D3E3597D9F0Q34016866-872F20E3-F8FD-45F7-8F17-6BB4422E19CBQ34498952-7920CF72-099A-4497-A5F5-5D3388030EDEQ34761663-3CB751EB-0C59-42EC-8896-BA4C78C45378Q35694453-AE0D724D-0E65-4EBB-9333-DD9DAE93AD3FQ36237990-1D6DB1B0-3E1F-430C-9D20-DFC482EA59A8Q36353183-AFA67046-9E0D-4CF6-8004-32AEDE0BB082Q36374813-AED0889A-CACD-41DA-A8CA-26CA58267CA8Q36612527-A6B6270D-E159-456E-9152-1E9AF5CABEF0Q36804884-6EB34797-9153-4808-B8CF-F1403C2AEA05Q37004660-B3758957-25DA-40D4-8444-7E034445BCD8Q37027767-56C52596-854E-4D0B-99CC-1995C2FEFFD6Q37095355-C1F3BCB3-087E-4B1D-B25C-85B1E77E943DQ37112773-F9DF99CF-509F-4714-87A9-1C55028B3CF3Q37148391-C566F526-C219-4F60-B729-9786B641F535Q37428659-73DBFB29-4CA8-4BCF-B080-8F96614A55FCQ37448763-25B4F134-673D-4624-8B77-0A27AA8D9139Q37542270-008F971A-0ACA-4D7F-962D-1924A16ABC87Q37657478-4448EAB2-F13D-47F8-BD32-C7A885C2F019Q37696776-080DDD8C-BA32-48C4-AEE4-E31612C0E1D7Q37810110-94866EA4-B76D-44C7-8335-6FA6E78EC4B5Q37974490-9625C838-E7FC-4A51-BCF5-C56009312504Q38057413-FFC8918B-5B59-4127-AEEB-CDBC30ADB828Q38142258-9445A27C-52E1-4C58-B6E4-B5DC4FE07696Q38181149-2E7E488E-3E6B-4C77-BF7B-C75B65E068DCQ38762203-FCFEFD35-4B76-4C32-B0DD-CBA88C6A73CAQ38802249-9FCA665E-51C8-4F5B-9500-58B9951A4FE5Q38828713-32DEF98E-DA03-49E5-BB47-28C75A61937BQ40095759-AD3BC759-DF7B-458A-A76F-CB61555E4084Q41294047-4916C9ED-1168-4630-9D16-DE3111EAC707Q41594071-06CA1FB0-D48D-4015-974B-4C2F385186BEQ41768874-316682CE-0C2A-42C8-A257-2A5744245B84Q41820783-227B2EA7-D43C-4FDE-A405-08E622B5557BQ42970294-852984BB-07AA-4CDC-B25C-97F97ABCECD9Q44394170-62CBA0DC-3121-44A7-83FB-08656B6B9C95Q45988194-4721FD46-679C-468D-BD49-60C50EE532EDQ47149685-20380CB8-E021-468F-97A8-EFCC9F3FA592
P2860
Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Molecular monitoring of BCR-AB ...... in chronic myeloid leukaemia.
@ast
Molecular monitoring of BCR-AB ...... in chronic myeloid leukaemia.
@en
type
label
Molecular monitoring of BCR-AB ...... in chronic myeloid leukaemia.
@ast
Molecular monitoring of BCR-AB ...... in chronic myeloid leukaemia.
@en
prefLabel
Molecular monitoring of BCR-AB ...... in chronic myeloid leukaemia.
@ast
Molecular monitoring of BCR-AB ...... in chronic myeloid leukaemia.
@en
P1433
P1476
Molecular monitoring of BCR-AB ...... in chronic myeloid leukaemia.
@en
P2093
Susan Branford
Timothy Hughes
P356
10.1016/J.BLRE.2005.01.008
P577
2005-03-02T00:00:00Z